FinancialTOHO HOLDINGS CO.
Financial Results for the First Half of Fiscal Year Ending March 2018: Japan
1 Nov 201714 pages~21 min full read
Toho Holdings reported a 3.2% year-on-year decline in net sales to 595,962 million yen and a 28.6% drop in operating income to 5,458 million yen for the first half of fiscal year 2018.
See it on page 1The dispensing pharmacy business was a key growth driver, with net sales increasing 2.2% to 48,204 million yen and segment income surging 590.1% to 1,305 million yen.
See it on page 4The company's core pharmaceutical wholesaling segment experienced a 3.6% decline in net sales, totaling 570,639 million yen, largely due to a shrinking prescription market and reduced demand for hepatitis C drugs.
See it on page 4Despite the overall decline in profitability, management maintained its full-year earnings projections as originally announced in May 2017.
See it on page 1Strategic efforts remain focused on the expansion of the generic drug brand KYOSOMIRAI PHARMA and the deployment of value-added support systems for medical institutions.
See it on page 4As of September 30, 2017, the company reported total assets of 633,584 million yen and a shareholder’s equity ratio of 30.4%.
See it on page 6Toho Holdings Co., Ltd. reported its consolidated financial results for the first half of the fiscal year ending March 2018, covering the period from April 1, 2017, to September 30, 2017. The primary objective of the report is to disclose the company’s operational performance and financial position within the Japanese medical, healthcare, and nursing care sectors. Despite a challenging market environment characterized by a decline in the prescription pharmaceuticals market and a significant reduction in demand for hepatitis C curative drugs, the company exceeded its internal budget projections for net sales and operating income.
Key financial data for the first half of fiscal year 2018 show net sales of 595,962 million yen, representing a 3.2% year-on-year decrease. Operating income fell by 28.6% to 5,458 million yen, while ordinary income and profit attributable to owners of the parent declined by 20.4% and 25.5%, respectively. The pharmaceutical wholesaling business, the company’s primary segment, recorded 570,639 million yen in net sales, a 3.6% decrease. Conversely, the dispensing pharmacy business demonstrated growth, with net sales rising 2.2% to 48,204 million yen and segment income increasing significantly by 590.1% to 1,305 million yen.
The company continues to focus on strategic initiatives, including the expansion of its generic drug brand, KYOSOMIRAI PHARMA, and the implementation of value-added customer support systems for medical institutions. As of September 30, 2017, total assets stood at 633,584 million yen, with a shareholder’s equity ratio of 30.4%. Management has maintained its full-year earnings projections, citing no changes to the forecasts previously announced in May 2017. The report is based on consolidated financial statements and is exempt from a formal quarterly review.
